PIA
LAB icon

Piedmont Investment Advisors’s Standard BioTools LAB Stock Holding History

Piedmont Investment Advisors’s Portfolio LAB Stock Details LAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-456
Closed -$3K – 1699
2018
Q2 		$3K Buy
+456
New +$2.6K ﹤0.01% 2394
2016
Q4 		– Sell
-186
Closed -$1.49K – 686
2016
Q3 		$1.49K Buy
+186
New +$1.71K ﹤0.01% 429

Other funds holding LAB

LCS
Levin Capital Strategies New York $1.32B AUM 28.11% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ECM
Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return

Piedmont Investment Advisors's LAB Position: Q3 2018 in Review

Piedmont Investment Advisors sold out of Standard BioTools (LAB) in Q3 2018, closing a stake of 456 shares — an estimated $3K sold.

Piedmont Investment Advisors first reported a position in LAB in Q3 2016 and held it in 2 quarters. The position peaked at $3K in Q2 2018. 79 funds tracked by Wall St. Rank hold LAB as of Q3 2018.

  • Piedmont Investment Advisors reported no remaining Standard BioTools position as of Q3 2018 after selling out during the quarter.
  • Piedmont Investment Advisors sold 456 Standard BioTools shares in Q3 2018, an estimated $3K.
  • Piedmont Investment Advisors first reported a position in Standard BioTools in Q3 2016 and held it in 2 quarters.
  • Piedmont Investment Advisors's Standard BioTools position peaked at $3K in Q2 2018.
  • 79 funds tracked by Wall St. Rank held Standard BioTools as of Q3 2018.

Based on Piedmont Investment Advisors's 13F filing for Q3 2018, filed 8 Nov 2018.